• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Accommodating IOL leads revenue surge

Article

Aliso Viejo, CA-First-quarter 2007 revenues for eyeonics inc., the developer of the crystalens accommodating IOL, have increased 36% over the same period last year, the company said.

Aliso Viejo, CA-First-quarter 2007 revenues for eyeonics inc., the developer of the crystalens accommodating IOL, have increased 36% over the same period last year, the company said.

For the first quarter ended March 31, revenues totaled $5.5 million.

During this period, the sale of implants grew more than 45% year over year, the company reported. The crystalens, the first and only FDA-approved accommodating IOL, has been implanted in more than 70,000 patients worldwide.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
© 2024 MJH Life Sciences

All rights reserved.